Comment on “Impact of Metastatic Pattern on Survival Following Pancreatectomy for Cancer”

We read with great interest the article titled "Impact of Metastatic Pattern on Survival Following Pancreatectomy for Cancer" by Gunder et al. published in the Journal of Surgical Oncology [1]. The study provides valuable insights into the differential survival outcomes based on metastatic patterns in pancreatic ductal adenocarcinoma (PDAC) patients, particularly highlighting the poor prognosis associated with peritoneal metastases post-surgery. While the findings are significant, we would like to offer some comments and suggestions that could further enhance the study's impact and provide additional context for future research. The study acknowledges the heterogeneity in treatment protocols, particularly in the use of neoadjuvant and adjuvant therapies. However, the impact of these treatments on survival outcomes, especially in the context of metastatic patterns, could be further explored. For instance, recent studies have shown that neoadjuvant therapy can significantly influence survival in PDAC patients. A meta-analysis by Versteijne et al. demonstrated that neoadjuvant therapy improved overall survival (OS) in patients with resectable and borderline resectable pancreatic cancer compared to upfront surgery [2]. Incorporating a more detailed analysis of the types and durations of neoadjuvant and adjuvant therapies used in your cohort could provide deeper insights into how these treatments modulate metastatic patterns and survival. The study highlights the poor prognosis associated with peritoneal metastases, which aligns with existing literature. However, emerging evidence suggests that cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) may offer a potential therapeutic avenue for patients with peritoneal metastases. A recent study by Yan et al. demonstrated that CRS combined with HIPEC improved survival in PDAC patients with peritoneal metastases, with a median OS of 24.2 months, suggesting an improvement over traditional therapies [3]. Including a discussion on the potential role of CRS and HIPEC in managing peritoneal metastases could provide a more comprehensive view of treatment options for this subset of patients. The study suggests that the presence of occult peritoneal tumor cells (OPTC) may contribute to the poor prognosis observed in patients with peritoneal metastases. Expanding on this, future research could explore the role of molecular profiling and biomarkers in predicting metastatic patterns and survival outcomes. Incorporating molecular profiling into the analysis could help identify patients at higher risk for peritoneal metastases and guide personalized treatment strategies. The study found that patients with peritoneal metastases had worse OS even when treated with palliative chemotherapy, suggesting that these patients may be less responsive to systemic therapy. This finding could be further explored by examining the specific chemotherapy regimens used and their efficacy in treating peritoneal disease. For instance, FOLFIRINOX and gemcitabine-based regimens are commonly used in PDAC, but their effectiveness in peritoneal metastases remains unclear. Analyzing the response rates of different chemotherapy regimens in patients with peritoneal metastases could provide valuable insights into optimizing systemic therapy for this challenging patient population. The study briefly mentions long-term survivors but does not delve deeply into the factors contributing to their prolonged survival. Analyzing the characteristics of long-term survivors, such as tumor biology, treatment response, and recurrence patterns, could provide valuable insights into the factors that influence survival in PDAC. In conclusion, the study by Gunder et al. provides important insights into the impact of metastatic patterns on survival in PDAC patients. However, further exploration of treatment heterogeneity, emerging therapies like CRS and HIPEC, molecular profiling, and the characteristics of long-term survivors could enhance the study's findings and provide a more comprehensive understanding of this complex disease. We commend the authors for their valuable contribution to the field and look forward to future research that builds on these findings. Wei Liu drafted and reviewed the article. The author has nothing to report. The author declares no conflicts of interest. The author has nothing to report.